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Objective. Five loci—the shared epitope (SE) of HLA-DRB1, the PTPN22 gene, a locus on 6q23, the STAT4 gene and a locus mapping to
the TRAF1/C5 genetic region—have now been unequivocally confirmed as conferring susceptibility to RA. The largest single effect is
conferred by SE. We hypothesized that combinations of susceptibility alleles may increase risk over and above that of any individual
locus alone.
Methods. We analysed data from 4238 RA cases and 1811 controls, for which genotypes were available at all five loci.
Results. Statistical analysis identified eight high-risk combinations conferring an odds ratio >6 compared with carriage of no susceptibility
variants and, interestingly, 10% population controls carried a combination conferring high risk. All high-risk combinations included SE, and all
but one contained PTPN22. Statistical modelling showed that a model containing only these two loci could achieve comparable sensitivity and
specificity to a model including all five. Furthermore, replacing SE (which requires full subtyping at the HLA-DRB1 gene) with DRB1*1/4/10
carriage resulted in little further loss of information (correlation coefficient between models¼0.93).
Conclusions. This represents the first exploration of the viability of population screening for RA and identifies several high-risk genetic
combinations. However, given the population incidence of RA, genetic screening based on these loci alone is neither sufficiently sensitive nor
specific at the current time.
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Introduction
RA (MIM 180300) is a complex autoimmune disease character-
ized by chronic inflammation and destruction of synovial joints,
leading to disability and joint damage. It affects an estimated
0.8% of the UK population, and imposes a significant economic
burden on healthcare systems [1]. Both genetic and environmental
factors contribute to the aetiology. The heritability of RA has
been estimated to be between 50 and 60% [2] suggesting that
the genetic component of the disease has a significant impact on
disease susceptibility.
The strongest genetic association with RA susceptibility has
been established since 1970s and lies within the HLA region [3],
in particular HLA-DRB1 (MIM 142857). Alleles associated with
RA share a conserved amino acid sequence in the third hyper-
variable region of the DR 1 chain and are referred to as the
shared epitope (SE) [4]. The SE has reproducibly been shown to
be associated with RA susceptibility and severity in many different
populations.
More recently, other RA susceptibility loci have been identified
and confirmed. A non-synonymous single nucleotide polymorph-
ism (SNP) in the gene encoding protein tyrosine phosphatase
non-receptor 22 (PTPN22) (MIM 600716)—R620W—confers
the second largest risk of susceptibility to RA [5]. A locus lying
between OLIG3 (MIM 609323) and TNFAIP3 (MIM 191163) on
chromosome 6q was identified in a genome-wide association study
(GWAS) of seven common diseases, including RA, carried out by
the WTCCC [6]. Association with 6q23 has been replicated in
populations from the UK and USA [7, 8]. A GWAS in US and
Swedish populations identified a novel locus mapping between
TRAF1 (MIM 601711) and C5 (MIM 120900) associated with
RA [9]. This association has been replicated in samples from
UK, Greek, Dutch and North American populations [9–12].
Finally, the STAT4 (MIM 600558) locus has been identified as
a confirmed RA susceptibility locus in UK, Korean, Swedish, US,
Greek, Colombian, Spanish and US populations [12–17].
The identified loci are neither necessary nor sufficient to cause
RA. The largest single effect comes from the SE [odds ratio (OR)
ranging from 2 to 3] with effect sizes for the other susceptibility
genes ranging from 1.1 to 1.8. It is hypothesized that combinations
of susceptibility alleles may further increase the risk of RA.
Indeed, several commercial companies offer genetic screening
tests to the general public quantifying the level of risk of develop-
ing RA over a lifetime. The loci tested vary and not all include the
confirmed loci listed above. In particular, the SE is not included in
any of the tests, presumably because the cost of subtyping at the
HLA-DRB1 locus to define SE alleles is both time consuming
and expensive. As SE confers the highest single genetic risk of
RA, calculations failing to incorporate this factor may lead to
inaccurate risk predictions.
The aim of the current work was, first, to investigate
whether combinations of five confirmed RA susceptibility
loci were associated with higher risk of developing RA than
SE alone; secondly, to explore the extent of information loss by
replacing SE subtyping with DRB*01, *04, and *10 broad
typing as this could influence screening costs dramatically and,
thirdly, to assess whether genotyping at these loci alone
would be useful for population screening to identify ‘at risk’
individuals.
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Subjects
A total of 4238 RA cases and 1811 controls were selected, for
whom individual genotype data were available at all five suscept-
ibility loci. These data were generated for previously published
studies [6, 8, 10]. All RA cases were >18 years old, and satisfied
the ACR criteria for RA [18]. All cases and controls were
Caucasians from the UK, and all provided informed consent.
The study was approved by the North West Ethics Committee
(MREC 99/8/84).
Genotyping
Genotyping of the PTPN22, 6q23, STAT4 and TRAF1/C5 loci
was undertaken using the Sequenom MassArray platform as
described and published previously [8, 10, 19]. For HLA genotyp-
ing, genomic DNA was amplified using the Dynal RELI SSO
HLA-DRB1 kits as described previously [20]. PCR amplicons
were identified by a reverse line assay using sequence-specific
oligonucleotide (SSO) probes with the Dynal RELI SSO strip
detection reagent kit (http://www.dynalbiotech.com/). Assay
results were interpreted using the Pattern Matching Program
provided by Dynal (Invitrogen, Paisley, UK). Broad HLA geno-
typing and subtyping were performed to identify the presence
of the SE in the HLA-DRB1 locus.
Susceptibility loci tested
For each of the five susceptibility loci selected for investigation,
the most significantly associated SNP identified to date in the UK
population was tested, except in the case of the SE where full
subtyping was available. Susceptibility loci were defined as:
PTPN22, carriage of the minor risk allele T at rs2476601; 6q23,
carriage of the minor risk allele A at rs6920220; STAT4, carriage
of the minor risk allele T at rs7574865; TRAF1/C5, carriage
of the major risk allele A at rs10760130; SE, defined by the
presence of any of the following alleles: HLA-DRB1*0101,
HLA-DRB1*0102, HLA-DRB1*0104, HLA-DRB1*0401, HLA-
DRB1*0404, HLA-DRB1*0405, HLA-DRB1*0408 and HLA-
DRB1*1001; and DRB1*01/04/10 status, defined as carriage of
either *01, *04 or *10 allele/s.
Statistical analysis
Statistical analysis of the data was carried out using STATA
version 9.2. Analysis was conducted by carriage of the risk allele
for each locus: carriage of the risk allele at each locus was defined
as 1, and not carrying the risk allele was defined as 0. Therefore,
for the five loci, 32 (2
5) possible gene combinations were identi-
fied. Logistic regression was performed and genotypic ORs and
CIs for each gene combination were generated. High-risk combi-
nations were arbitrarily defined as those conferring an OR >6 and
with 95% CIs that did not encompass unity. ORs were compared
with base odds of the population, who did not carry risk alleles at
any of the susceptibility loci to create comparable OR. If carriage
of a particular combination was compared with non-carriage,
different individuals would be included in the denominator result-
ing in non-comparable OR. Each individual could only be
included once in the table.
ORs were calculated as:
B0Ci
A0Di
where B0 denotes controls with no risk alleles; A0 denotes cases
with no risk alleles; Di denotes controls with the i-th combination
of risk alleles; and Ci denotes cases with i-th combination of risk
alleles. Numbers of cases and controls for each allele combination
class were tabulated. As each individual can only appear once,
some genotype combinations were poorly represented; therefore,
results from any class with less than five individuals in the case
or control group were regarded as unreliable.
Statistical modelling was performed to determine whether the
five-locus model could be simplified, using maximum likelihood
tests implemented in STATA. First, combinations of SE carriage
with different numbers of the other four loci were compared with
the full model. Secondly, SE status was replaced by broad DRB*1,
*4 or *10 status and compared with the full model. Log likelihood
estimates showing the goodness of fit of the simplified model to
the full model were calculated. The sensitivity and specificity of
each model were calculated, setting probability thresholds at 80%.
For population-based screening, it is recommended that a model
should have >80% power of discrimination, in order to be useful
in the identification of high-risk individuals [21]. Receiver opera-
tor curve (ROC) curves were generated, defining the sensitivity
and specificity of each model, and the area under the curves was
compared. Likelihood ratios were calculated and, from these,
chi-square tests highlighted any significant differences between
the models. Correlation coefficients of the models were compared
to the full model. Sensitivity and specificity were compared using
the ‘diagt’ command in STATA, which calculates summary
statistics of a diagnostic test using a 2 2 table. Numbers of
true positives, false negatives, false positives and true negatives
defined by the test are compared with the true disease status of
each individual to calculate the sensitivity and specificity.
Gender analysis
RA is three times more prevalent in women; therefore, the analysis
was also performed with stratification by gender to investigate
whether different genetic risk combinations were present in
males and females.
Stratification by anti-citrullinated peptide antibody status
There is increasing evidence of differences in risk conferred by
the loci identified in anti-citrullinated peptide (anti-CCP)-positive
and -negative individuals. Analyses were therefore repeated in the
anti-CCP antibody-positive subgroup.
Results
Clinical characteristics
The clinical and demographic features of the cases included in the
analysis are shown in Table 1, and are typical of a hospital-based
cohort of RA subjects.
Identification of high-risk combinations including SE
Statistical analysis of the whole dataset (6049 individuals) is
shown in Table 2. Approximately 14% of the controls carried a
combination of genotypes that conferred a relative risk of >5 and
 10% carried >6 compared with carriage of no susceptibility
variants. In total, eight combinations resulted in a relative risk
of RA >6 compared with carriage of no susceptibility variants.
All contained SE and all but one contained PTPN22.
TABLE 1. Clinical and demographic data
Characteristics Cases, n (%) Controls, n (%)
Male 1493 (35.3) 803 (44.6)
Female 2738 (64.7) 999 (55.4)
Caucasians 4238 (100) 1811 (100)
Erosions 697 (68.7) NA
Nodules 750 (35) NA
RF positive 1781 (71) NA
Anti-CCP positive 1100 (66.5) NA
Clinical and demographic data were not available for all individuals. Percentages are given
as a percentage of the data available.
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STAT4þTRAF1/C5 (OR¼9.94; 95% CI 5.45, 18.10) followed
by SEþPTPN22 (OR¼9, 95% CI 4.02, 20.16) alone. In order
to calculate the risk of carriage of SE and PTPN22 compared
with the rest of the population as opposed to just those subjects
with carriage of no susceptibility alleles at any of the five loci, a
further analysis was carried out comparing a group carrying
SEþPTPN22 regardless of other susceptibility loci (1033 individ-
uals), against a group negative for both SE and PTPN22 (1520
individuals), resulting in an OR of 5.53 (95% CI 4.54, 6.73).
Simplifying the model
As both SE and PTPN22 were included in all but one of the high-
risk combinations in Table 2, we first investigated whether these
two loci alone would give as much information as including all
five loci in the model. ROC curve analysis showed that the areas
under the ROC curves were similar (0.67 full model, 0.66
SEþPTPN22 model) (Fig. 1), and the correlation coefficient
between the two models was 0.98. However, the difference
between the models was statistically significant (P¼0.0004); this
arises due to the size of the study, meaning that trivial differences
of no practical importance achieve statistical significance.
Replacing DR*01/*04/*10 status for SE status
The analysis was repeated including broad HLA-DRB1 typing in
place of full subtyping. For that analysis, carriage of any DR*01,
DR*04 or DR*10 allele denoted an individual as SE positive.
The results are shown in Table 3 and are very similar to the results
including SE subtypes. ROC analysis showed that the area under
the curve was similar to the full model (0.65), and the correlation
coefficient was 0.93. Again, however, statistical comparison
showed a significant difference between the areas under the two
curves (P¼2 10
 6).
An additional model containing DR*01/*04/*10 and PTPN22
was compared with the previous SEþPTPN22 model. ROC
analysis showed that the area under the curve was similar to the
SEþPTPN22 model (0.64), although it was slightly reduced by the
exclusion of the other four loci. The correlation coefficient
between the two models was 0.93 (data not shown).
Choice of cost-efficient screening model
In terms of general population screening test, the genetic
factors included should be amenable to genotyping on medium-
throughput platforms in a time- and cost-efficient manner.
TABLE 2. Results for all 32 possible allele combinations
Allele combination class Combination OR (95% CI) Controls Cases Total
1 Negative for all 54 42 96
2 TRAF only 1.03 (0.66, 1.62) 230 185 415
3 STAT only 1.31 (0.74, 2.34) 45 46 91
4 STATþTRAF 1.30 (0.82, 2.07) 147 149 296
5 6q23 only 2.01 (1.10, 3.66) 32 50 82
6 6q23þTRAF 1.25 (0.78, 1.99) 136 132 268
7 6q23þSTAT 1.96 (0.99, 3.88) 21 32 53
8 6q23þSTATþTRAF 1.62 (1, 2.62) 97 122 219
9 PTPN22 only 1.45 (0.66, 3.17) 16 18 34
10 PTPN22þTRAF 1.29 (0.76, 2.19) 64 64 128
11 PTPN22þSTAT 3.64 (1.32, 10.04) 6 17 23
12 PTPN22þSTATþTRAF 2 (1.11, 3.62) 34 53 87
13 PTPN22þ6q23 1.93 (0.72, 5.15) 8 12 20
14 PTPN22þ6q23þTRAF 2.62 (1.43, 4.80) 28 57 85
15
a PTPN22þ6q23þSTAT 0.57 (0.16, 1.98) 9 4 13
16 PTPN22þ6q23þSTATþTRAF 3.51 (1.72, 7.19) 15 41 56
17 SE only 3.75 (2.27, 6.18) 59 172 231
18 SEþTRAF1 3.92 (2.54, 6.05) 200 610 810
19 SEþSTAT4 4.56 (2.59, 8.04) 31 110 141
20 SEþSTATþTRAF 3.94 (2.52, 6.15) 140 429 569
21 SEþ6q23 4.36 (2.49, 7.64) 33 112 145
22 SEþ6q23þTRAF 4.21 (2.70, 6.58) 138 452 590
23 SEþ6q23þSTAT 5.98 (3.19, 11.22) 20 93 113
24 SEþ6q23þSTATþTRAF 5.23 (3.28, 8.33) 89 362 451
25 SEþPTPN22 9 (4.02, 20.16) 96 37 2
26 SEþPTPN22þTRAF 6.91 (4.08, 11.69) 40 215 255
27 SEþPTPN22þSTAT 8.57 (3.32, 22.12) 64 04 6
28 SEþPTPN22þSTATþTRAF 9.94 (5.45, 18.10) 22 170 192
29 SEþPTPN22þ6q23 4.82 (2.27, 10.24) 12 45 57
30 SEþPTPN22þ6q23þTRAF 5.84 (3.41, 10) 37 168 205
31 SEþPTPN22þ6q23þSTAT 6.06 (2.44, 15.06) 73 34 0
32 SEþPTPN22þ6q23þSTAT4þTRAF 6.92 (3.87, 12.38) 26 140 166
Total 1811 4238 6049
ORs are compared with base odds of no susceptibility loci. High-risk combinations are highlighted in bold.
aAllele combination Class 15 has an OR of 0.57, suggesting a protective effect; however,
this is due to the low sample numbers making the result unreliable (nine controls and four cases).
0
.
0
0
0
.
2
5
0
.
5
0
0
.
7
5
1
.
0
0
S
e
n
s
i
t
i
v
i
t
y
0.00 0.25 0.50 0.75 1.00
1–Specificity
p_FULL ROC area: 0.6697
Reference
p_SE_PTPN22 ROC area: 0.6598
FIG. 1. ROC curve analysis comparing the full model containing all five suscept-
ibility loci (blue line) against the simpler model containing only SE and PTPN22
loci (red line).
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*04/*10 with the four other loci. DR*01/*04/*10 can be typed
using PCR sizing-based methods; whereas, for many multiplex
platforms, there would be little time or cost savings in genotyping
fewer SNPs (i.e. there would be no benefit in genotyping just the
PTPN22 locus rather than including the STAT, TRAF1/C5
and 6q23 loci as well). The combination of DR*01/*04/
*10þPTPN22þSTATþ6q23þTRAF has a sensitivity and spe-
cificity similar to the full model (Table 4), and the correlation
coefficient for the predicted probabilities of the two models was
0.93. For population-based screening models, it is recommended
that both sensitivity and specificity should exceed 80% [21].
Whereas all the models are specific (i.e. having a low risk of falsely
identifying a subject as being at high risk), even the best model
including SE and the remaining four risk variants lacks sensitivity
and, consequently, individuals at risk of developing disease will
be missclassified.
Stratification by gender
Analysis was repeated separately in male cases compared with
male controls and in female RA cases and female controls.
There was no statistically significant difference observed in
the high-risk combinations identified (Supplementary Tables 1
and 2, available as supplementary data at Rheumatology Online).
Stratification by CCP status
Statistical analysis was repeated in individuals who were known
to be anti-CCP positive (1100) and all controls (1811)
(Supplementary Table 3, available as supplementary data at
Rheumatology Online). Seventeen combinations resulted in a
relative risk of >6 compared with carriage of no susceptibility
variants. All but one high-risk combinations contained SE. The
highest risk was conferred by SEþPTPN22þSTAT4þTRAF1/
C5 (OR ¼ 21.39; 95% CI 8.47, 54) followed by SEþPTPN22
(OR ¼ 18.86; 95% CI 6.24, 56.94).
Discussion
We have shown that carriage of combinations of confirmed RA
susceptibility alleles can increase the risk of RA over and above
any risk allele alone. In particular, genotyping only the SE and
PTPN22 risk alleles was able to identify most individuals with an
OR >6 of developing RA compared with carriage of no risk
alleles. This is not surprising as these two loci confer the highest
genetic risk for susceptibility to RA individually.
Identification of a number of high-risk combinations, present at
an appreciable frequency in the control population, opens the
debate about population screening to identify a group at high
risk of developing RA. However, population screening using SE
is not commercially viable due to the time required and the
expense involved in subtyping for these susceptibility alleles.
Indeed, companies offering a screening service for the risk of
developing RA do not currently include SE among the loci
tested. Excluding this locus significantly reduces the sensitivity
TABLE 3. Results for all 32 allele combinations generated by replacing SE with DRB1*1\4\10
Allele combination class Combination OR (95% CI) Controls Cases Total
1 Negative for all 48 37 85
2 TRAF only 1.09 (0.68, 1.75) 206 173 379
3 STAT only 1.33 (0.71, 2.50) 36 37 73
4 STATþTRAF 1.27 (0.78, 2.07) 133 130 263
5 6q23 only 2.08 (1.11, 3.88) 30 48 78
6 6q23þTRAF 1.29 (0.78, 2.12) 120 119 239
7 6q23þSTAT 2.05 (1, 4.20) 19 30 49
8 6q23þSTATþTRAF 1.72 (1.03, 2.87) 86 114 200
9 PTPN22 only 1.60 (0.68, 3.73) 13 16 29
10 PTPN22þTRAF 1.32 (0.75, 2.32) 57 58 115
11 PTPN22þSTAT 3.46 (1.23, 9.71) 6 16 22
12 PTPN22þSTATþTRAF 2.24 (1.19, 4.19) 29 50 79
13 PTPN22þ6q23 1.78 (0.65, 4.88) 8 11 19
14 PTPN22þ6q23þTRAF 2.65 (1.38, 5.07) 24 49 73
15
a PTPN22þ6q23þSTAT 0.58 (0.16, 2.02) 9 4 13
16 PTPN22þ6q23þSTATþTRAF 3.34 (1.57, 7.07) 14 36 50
17 DRB1*1\4\10 only 3.53 (2.11, 5.91) 65 177 242
18 DRB1*1\4\10þTRAF1 3.60 (2.29, 5.68) 224 622 846
19 DRB1*1\4\10þSTAT4 3.86 (2.21, 6.75) 40 119 159
20 DRB1*1\4\10þSTATþTRAF 3.77 (2.37, 6.02) 154 448 602
21 DRB1*1\4\10þ6q23 4.23 (2.38, 7.49) 35 114 149
22 DRB1*1\4\10þ6q23þTRAF 3.92 (2.46, 6.24) 154 465 619
23 DRB1*1\4\10þ6q23þSTAT 5.60 (2.98, 10.54) 22 95 117
24 DRB1*1\4\10þ6q23þSTATþTRAF 4.80 (2.96, 7.78) 100 370 470
25 DRB1*1\4\10þPTPN22 7.03 (3.32, 14.88) 12 65 77
26 DRB1*1\4\10þPTPN22þTRAF 6.10 (3.58, 10.38) 47 221 268
27 DRB1*1\4\10þPTPN22þSTAT 8.86 (3.40, 23.11) 64 14 7
28 DRB1*1\4\10þPTPN22þSTATþTRAF 8.31 (4.61, 15) 27 173 200
29 DRB1*1\4\10þPTPN22þ6q23 4.97 (2.31, 10.70) 12 46 58
30 DRB1*1\4\10þPTPN22þ6q23þTRAF 5.57 (3.22, 9.62) 41 176 217
31 DRB1*1\4\10þPTPN22þ6q23þSTAT 6.12 (2.43, 15.37) 73 34 0
32 DRB1*1\4\10þPTPN22þ6q23þSTAT4þTRAF 6.97 (3.85, 12.62) 27 145 172
Total 1811 4238 6049
ORs are compared with base odds of no susceptibility loci. High-risk combinations are highlighted in bold.
aAllele combination Class 15 shows a protective OR; however, this is due to the low sample
numbers making the result unreliable.
TABLE 4. Sensitivity and specificity of screening models
Model Sensitivity, % Specificity, %
Full 31.4 85.2
SEþPTPN22 20.6 91.2
DRB1*1/4/10þfour loci 21.2 90.1
Probability thresholds were set at >0.8 for all models. The full model is based on carriage of:
SE, plus PTPN22, STAT4, TRAF1 and 6q23 risk alleles; SEþPTPN22 model is based on
carriage of: SE and PTPN22 risk allele; DRB*1\4\10 þ four loci model is based on carriage of:
DRB1*1\4\10, plus PTPN22, STAT4, TRAF1 and 6q23 risk alleles. See ‘Materials and Methods’
section for classification of carriage.
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Figure 1, available as supplementary data at Rheumatology
Online). For example, removal of SE information reduced the
number of possible gene combinations from 32 to 16, and of
those 16 gene combinations, the greatest risk was conferred
by PTPN22þSTAT4 (OR 2.5). Hence, inclusion of the HLA-
DRB1 status appears essential. However, our data suggest that
DRB*01/*04/*10 broad typing can replace full HLA-DRB1
subtyping for SE with little loss in sensitivity and a gain in speci-
ficity; and a direct comparison of the OR shows little difference
(SE only: OR 3.75; Table 2) (DRB*01/*04/*10 only: OR 3.53;
Table 3).
There is increasing evidence that RA may be split into two
genetically distinct subsets based on the presence of antibodies
to CCPs. For example, although the SE confers the largest
genetic association with RA, this association is restricted to
anti-CCP-positive RA cases [22]. Therefore, subgroup analysis
was carried out to see if risk prediction could be improved
in this subset of individuals. Analysis of anti-CCP-positive
individuals increased the number of high-risk combinations
(OR >6) from 8 to 17; the highest relative risk was conferred by
SEþPTPN22þSTAT4þTRAF1/C5 (OR 21.39) compared with
9.94 in the original analysis. The area under the ROC curve was
also increased from 0.67 to 0.71, showing an increase in sensitivity
and specificity when all five susceptibility variants are genotyped
in anti-CCP-positive individuals. Stratification by anti-CCP
has shown that risk prediction is improved in this subset of
individuals; however, some individuals will still be misclassified.
Ideally, it would also be important to test whether the models
can accurately predict the risk of developing RA in a particular
year. As the background risk of RA is at best 1:1000 per annum
[1], genetic screening alone is unlikely to identify a group at very
high risk. For example, the high-risk combinations identified
in the current study increase risk compared with subjects not
carrying any of the risk alleles and even then, an OR 6 still equates
to a small absolute risk of developing RA. Although the model
discriminates reasonably well between low-risk (OR <2) and high-
risk (OR >5) groups (OR 5.12; 95% CI 4.32, 6.06), the absolute
risk, calculated by combining all individuals at high risk (OR >5)
and comparing them to the rest of the cohort results in an OR of
2.64 (95% CI 2.27, 3.07), suggesting a model based on these
genetic loci is not sufficient to predict the risk. Furthermore,
the sensitivity and specificity of the models using only genetic
information are not sufficiently accurate to support population
screening. An alternative approach would be to use genetic screen-
ing in a population that is already identified as being at higher risk
of disease due to the presence of other predisposing factors; this is
termed as genetic testing. Several environmental risk factors have
been identified and confirmed in different populations. These
include age, gender, family history, smoking history, obesity,
a history of an adverse pregnancy outcome as well as other factors
(reviewed in [23]). It will require further investigation to determine
whether a two-stage screening process in which genetic testing was
undertaken in individuals with environmental RA susceptibility
factors could identify a group at high enough risk to recommend
intervention. Furthermore, previous studies have found that
specific SE allele combinations confer a higher risk than others
[24]. It may be that these high-risk SE genotypes, combined with
the other established RA risk loci, could be used to identify a
group of individuals at very high risk of RA. Such individuals
could be offered lifestyle advice, or be followed closely such that
early intervention could be offered as soon as symptoms or signs
of inflammatory arthritis became apparent. This is particularly
important as there is mounting evidence that a ‘window of
opportunity’ exists during which early diagnosis and treatment
of RA can reduce the extent of joint damage, and could also
help limit the involvement of extra articular tissues [25, 26].
Unfortunately, it was not possible to include environmental
risk factors in the current analysis. As further susceptibility
factors, both genetic and environmental, emerge from ongoing
studies, the number of possible combinations increases exponen-
tially. For example, the inclusion of another risk factor would
increase the number of possible combinations to 64. Despite test-
ing large numbers of cases and controls with information at the
five susceptibility loci in the current study, there remained some
genetic combinations for which results were unreliable, because of
the insufficient numbers of subjects carried those combinations.
Hence, to incorporate additional risk factors, it will be necessary
to investigate combinations in even larger sample sizes so that
accurate predictive models can be developed [27]. A limitation
of this study is that the analysis has been confined to Caucasian
individuals, meaning that the model could not be extended to a
more ethnically diverse population. However, depending on the
origins of the population tested, different susceptibility loci may
need to be included within the model; for example, the PADI4
gene has reproducibly been associated with RA in a Japanese
population but not in a Caucasian population [28].
Our analysis presents a thorough exploration of the viability of
population screening for RA incorporating the five most widely
confirmed susceptibility loci identified, to date, in large sample
sizes. We conclude that population screening based on these
genetic loci alone cannot currently be recommended. This is in
line with several recent studies which have concluded that, even
in diseases such as prostate cancer and breast cancer, with a higher
prevalence in the population than RA, whole population screen-
ing using genetics alone does not provide the sensitivity and
specificity required to accurately classify individuals at high risk
[21, 29–31]. Further work to test whether genetic testing in
patients with established risk factors including family history
can be used to identify a group at very high risk of disease is
required.
Although we have shown that genetic screening for RA is not
currently viable, it may become so in the future; and this type of
analysis represents a step en route to using genetics in a fully
translational approach to inform clinical practice.
Rheumatology key messages
  Combinations of RA susceptibility factors increase risk of disease
above any one factor alone.
  Genetics alone cannot currently accurately predict an individual’s
risk of disease.
  Genetic screening for RA is not currently viable, although it may be
in the future.
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